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Unique microbial communities persist in
individual cystic fibrosis patients throughout a
clinical exacerbation
Katherine E Price1, Thomas H Hampton1, Alex H Gifford2, Emily L Dolben1, Deborah A Hogan1, Hilary G Morrison3,
Mitchell L Sogin3 and George A O’Toole1*
Abstract
Background: Cystic fibrosis (CF) is caused by inherited mutations in the cystic fibrosis transmembrane conductance
regulator gene and results in a lung environment that is highly conducive to polymicrobial infection. Over a
lifetime, decreasing bacterial diversity and the presence of Pseudomonas aeruginosa in the lung are correlated with
worsening lung disease. However, to date, no change in community diversity, overall microbial load or individual
microbes has been shown to correlate with the onset of an acute exacerbation in CF patients. We followed 17
adult CF patients throughout the course of clinical exacerbation, treatment and recovery, using deep sequencing
and quantitative PCR to characterize spontaneously expectorated sputum samples
Results: We identified approximately 170 bacterial genera, 12 of which accounted for over 90% of the total
bacterial load across all patient samples. Genera abundant in any single patient sample tended to be detectable in
most samples. We found that clinical stages could not be distinguished by absolute Pseudomonas aeruginosa load,
absolute total bacterial load or the relative abundance of any individual genus detected, or community diversity.
Instead, we found that the microbial structure of each patient’s sputum microbiome was distinct and resilient to
exacerbation and antibiotic treatment.
Conclusion: Consistent with previously reported sputum microbiome studies we found that total and relative
abundance of genera at the population level were remarkably stable for individual patients regardless of clinical
status. Patient-by-patient analysis of diversity and relative abundance of each individual genus revealed a complex
microbial landscape and highlighted the difficulty of identifying a universal microbial signature of exacerbation.
Overall, at the genus level, we find no evidence of a microbial signature of clinical stage.
Keywords: Cystic fibrosis, Cystic fibrosis pulmonary exacerbation, Microbiome, Sputum, Pseudomonas aeruginosa
Background
Cystic fibrosis (CF) is a human genetic disorder caused
by mutations in the cystic fibrosis transmembrane con-
ductance regulator (CFTR) gene. Mutations in the CFTR
gene lead to decreases in periciliary fluid layer and in-
creased volume and viscosity of mucus in the lungs,
resulting in an environment highly conducive to micro-
bial growth. The lungs of CF patients eventually become
permanently colonized and chronically inflamed leading
to gradual pulmonary function decline and the bulk of
CF-associated mortality [1-5]. This inflammatory process
includes acute CF pulmonary exacerbations (CFPEs) char-
acterized by decreased lung function, changes in cough,
sputum production, shortness of breath, decreased energy
level and appetite, and weight loss [6]. Patients experien-
cing a CFPE typically require hospitalization and receive
intravenous antibiotics chosen based on the antibiotic
resistance profiles of Pseudomonas aeruginosa.
Conventional culturing techniques using sputum or
bronchial alveolar lavage (BAL) samples have identified* Correspondence: georgeo@Dartmouth.edu1Department of Microbiology and Immunology, Geisel School of Medicine at
Dartmouth, Hanover, NH 03755, USA
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several key microbes that contribute to CF lung infection
and disease progression. These techniques have revealed
that CF lung colonization generally begins early in life
with Staphylococcus aureus and Haemophilus influenzae,
which are later supplanted by P. aeruginosa. This change
in microbial colonizers, specifically the appearance of
P. aeruginosa, is associated with decreasing lung function
[7-9]. Advances in culture-independent, deep-sequencing
technology have revealed that the landscape of microbes
in the CF lung is much richer than previously appreciated.
Deep sequencing of the CF-derived sputum and BAL
samples has revealed that there are dozens of bacterial
genera present, including Streptococcus and a variety
of anaerobes including Prevotella, Fusobacterium and
Veillonella [10-20]. The relative contribution by these
newly identified members of the CF airway microbiome
to clinical status and disease progression, however, is
still unclear. Total bacterial load (or load of Pseudomonas
in particular) has been reported to be a poor predictor
of exacerbations [21]. Previous reports have suggested a
role for bacterial diversity as a determinant of clinical
stability over the long term [11,16-20,22]. It is unclear
whether increased diversity is directly beneficial to the
patient or if increased diversity correlates with stable
disease because stable patients experience fewer exacer-
bations and therefore fewer exposures to antibiotics.
Whether the effect is direct or indirect, thus far, bacterial
diversity has not been shown to predict the onset of an
exacerbation [11,19].
Here, we build on these studies, testing the hypoth-
esis that there is a microbial signature of CF exacerba-
tions. To identify such a microbial signature of CF
exacerbations, we followed the short-term microbiome
dynamics both at the community population level and
organism-by-organism in an independent cohort of
adult CF patients. Although we detected over 170 bac-
terial genera, 12 genera account for approximately 90%
of the bacterial diversity across all samples, consistent
with our finding that high abundance in a single sample
is correlated with prevalence across all samples. Genera
that thrive in a single patient tend to be present in most
patients. We found that patient microbial communities
were highly distinct and observed remarkable stability
and resilience throughout the exacerbation cycle. We
analyzed short-term microbiome dynamics, organism-
by-organism, as a function of transition from one
clinical state to the next, and found no evidence of a
microbial signature of exacerbation, consistent with
several previous studies that measured the population
dynamics of the sputum microbiome [11,19,23]. Over-
all, we found that the microbial communities in the
sputum of individual CF patients are both distinct and
resilient throughout the stresses of an exacerbation and
antibiotic treatment.
Methods
Patient cohort, sample collection and genomic DNA
preparation
As described by Gifford et al. [24], 17 adult CF patients
were recruited to the study. The Committee for the Pro-
tection of Human Subjects (CPHS) at Dartmouth College
approved the sputum collection protocol (CPHS #22506)
and all patients provided written informed consent prior
to participating in the study. Patient ages, FEV1, antibiotics
administered at exacerbation and dates of sample collec-
tion are listed in Additional file 1: Table S1.
Genomic DNA was isolated from spontaneously ex-
pectorated sputum samples produced at four clinically
defined stages: baseline, exacerbation, treatment and re-
covery (BETR). Baseline samples were collected at a rou-
tine, quarterly clinic visit. Baseline samples are clinically
defined and include those that were collected before an
exacerbation occurred and after a full recovery from an
exacerbation. Exacerbation samples were obtained less than
24 hours after CFPE determination following admit-
tance to the hospital. Treatment samples were collected
less than 24 hours prior to completing hospital stay where
patients received intravenous (IV) antibiotics chosen
based on their clinical laboratory history of Pseudomonas
susceptibility and resistance profiles. Recovery samples
were taken at the next routine, quarterly visit to the
clinic. It should be noted that exacerbation sputum sam-
ples include samples that were taken before and after
the administration of IV antibiotics, but always within
24 hours of hospital admittance. Of the seventeen patients
analyzed in this study, we considered nine of these patient
sputum sample sets complete and eight incomplete.
Table 1 shows absolute bacterial abundance (copies 16s
rRNA/gram sputum). Six patients produced sputum at
all four BETR stages, and three patients produced sputum
at the baseline, exacerbation and recovery (BER) stages
but no sputum at the treatment stage, as their condition
improved such that they did not produce sputum at that
time point. The remaining eight patients were lost to
follow-up and/or have incomplete datasets due to missed
visits or late recruitment. For each analysis below, the
datasets used are indicated.
Community analyses
Genomic DNA (gDNA) was isolated from patient spu-
tum samples as previously described [18] for use in 454
pyrosequencing of the V4-V6 regions of the 16S rRNA
gene, and quantitative PCR (qPCR) analysis of total bac-
terial load and relative abundance of P. aeruginosa. Briefly,
gDNA was isolated with a modified protocol of the
Gentra PureGeneYeast/Bact. Kit. Patient sputum samples
were weighed and their mass noted before sputum sam-
ples were resuspended and diluted twofold to fivefold in
Tris-EDTA (TE) + 0.08% dithiothreitol (DTT). Diluted
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samples were passed repeatedly through syringes with
16, 20 and 23 gauge needles until homogeneous. Ho-
mogenates were treated with a final concentration of
3 mg/mL lysozyme for 30 minutes at 37°C. Samples
were then incubated in cell lysis buffer (Gentra) for
15 minutes at 80°C. gDNA from these treated samples
was isolated following the manufacturer’s protocol.
The resulting gDNA was used in deep sequencing and
qPCR analysis. gDNA for qPCR controls was prepared
using the Gentra PureGene Yeast/Bact. Kit according
to the manufacturer’s instructions for Gram-positive or
Gram-negative species as appropriate.
Deep sequencing, bioinformatic quality filtering and
operational taxonomic unit assignments were performed
as previously described [18]. Briefly, a custom bioinfor-
matics pipeline at the Marine Biological Laboratory per-
formed quality filtering to remove low quality reads
(average quality scores less than 30) and sequences lacking
exact primer matches or containing ambiguous bases
(Ns). Chimerical reads were removed using the UChime
algorithm, which combines the de novo and reference
database modes of ChimeraSlayer GOLD. A taxonomy
was assigned to each unique read by the GAST algo-
rithm; UCLUST identified the operational taxonomic
units with 97% sequencing identity. Individual reads, taxon
assignments and descriptions of individual clusters are
accessible on the website Visualization and Analysis
of Microbial Population Structures [25] and the NCBI
website [26], SRA study accession number SRP025173.
The absolute abundance of the total bacterial load per
gram of sputum sample was determined by qPCR using
methods similar to those previously published [11,21]
with universal primers to the 16S rRNA gene originally
described in Maeda et al., 2003 and evaluated in Horz et al.,
2005 for broad range amplification of bacterial species
(Universal For/Rev 5′-GTGSTGCAYGGYTGTCGTCA-
3′/5′-ACGTCRTCCMCACCTTCCTC-3′) [27,28]. The
number of 16S molecules in a given 10 ng qPCR reac-
tion was multiplied by the total number of nanograms
in the entire sputum gDNA prep and then divided by
the sputum mass at the time of collection to give an ab-
solute abundance of 16S molecules/gram sputum.
The relative abundance of P. aeruginosa was deter-
mined as previously described [18] using primers to the
P. aeruginosa housekeeping gene rplU (rplU For 5′-
GCAGCACAAAGTCACCGAAGG-3′ and rplU Rev 5′-
CCGTGGGAAACCACTTCAGC-3′) and universal primers
Universal For/Rev.
Statistical analyses
All statistical analyses were performed on taxa at the
level of genus normalized by the percentage within the
datasets where the frequency of each taxonomic assign-
ment was reported as a percentage (number of reads
assigned to a taxonomy over total number of reads in
the dataset). Heat maps were developed using complete
hierarchical clustering by Euclidian distance, using the
heatmap.2 function in R as implemented in gplots [29].
Principal coordinate analysis was performed using the
prcomp routine in pcaComp in R [30]. The Simpson di-
versity index was calculated at the genus level using the
diversity function in the R package vegan [31]. Mixed-
effect linear models with clinical stage as a categorical
fixed effect and patient as a random effect were gener-
ated in R to estimate diversity as a function of clinical
status using the lme package in R.
Results
Bacterial load in sputum does not correlate with
clinical stage
Bruce and colleagues reported that the absolute abun-
dance of Pseudomonas and other bacteria did not change
during the three weeks before an exacerbation occurs
[21]. We extend this work using similar methods to
include all clinical stages of an exacerbation (baseline,
exacerbation, treatment and recovery) in a larger, inde-
pendent cohort. We measured the total bacterial abun-
dance and the abundance of Pseudomonas by qPCR
normalized to sputum weight. The total bacterial load
per gram of sputum in all samples analyzed ranged from
8.42 × 106 to 2.39 × 1011 (Table 1, Figure 1A). The total
bacterial load (defined as the number of 16S molecules/
gram sputum) as well as the absolute abundance of
Table 1 Absolute abundance of total bacterial load in
each sample
Patient ID Baseline Exacerbation Treatment Recovery
100 4.36 × 10+9 3.71 × 10+10 2.16 × 10+9 2.40 × 10+10
101 6.73 × 10+10 8.97 × 10+10 6.15 × 10+9 6.60 × 10+10
200 4.02 × 10+10 1.45 × 10+10 2.45 × 10+8 1.07 × 10+11
204 5.73 × 10+10 5.23 × 10+9 1.78 × 10+10 8.42 × 10+6
207 4.10 × 10+10 1.23 × 10+9 1.41 × 10+10 1.60 × 10+10
212 4.02 × 10+9 1.99 × 10+10 1.61 × 10+10 1.30 × 10+10
201 1.38 × 10+10 2.59 × 10+10 n.s. 1.88 × 10+10
202 2.39 × 10+11 5.65 × 10+10 n.s. 1.24 × 10+10
205 9.37 × 10+9 1.51 × 10+10 n.s. 3.19 × 10+9
102 5.09 × 10+10 n.s. n.s. n.s
203 9.98 × 10+9 1.29 × 10+10 n.s. n.s.
206 n.s. n.s. 5.33 × 10+9 1.17 × 10+10
208 n.s. 1.07 × 10+10 n.s. n.s.
209 1.53 × 10+10 n.s. n.s. n.s.
210 n.s. 2.79 × 10+10 1.68 × 10+10 n.s.
211 5.70 × 10+10 3.66 × 10+9 n.s. n.s.
213 n.s. 4.32 × 10+10 9.30 × 10+10 n.s.
n.s, no sample.
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Pseudomonas (defined as the number of rplU molecules/
gram sputum), remained relatively stable throughout all
clinical stages, and ANOVA of the log-transformed data
revealed no significant difference among clinical stages for
total bacterial load (Figure 1A) or Pseudomonas absolute
abundance (Figure 1B). For example, as shown in Table 1,
six out of eleven patients with available measurements at
both time points saw an increased bacterial load as they
made the transition from baseline (B) to exacerbation (E),
but five out of eleven patients saw a decrease, consistent
with what one would expect by chance. Similarly, for the
nine patients with measurements during exacerbation (E)
that had available measurements at recovery (R), there
was no significant difference (P = 0.25). In summary, data
from spontaneously expectorated sputum support neither
the hypothesis that increases in bacterial load precipitate
exacerbation nor the hypothesis that recovery is achieved
by a reduction in bacterial load.
Figure 1 Neither absolute bacterial load nor absolute abundance of Pseudomonas correlates with clinical stage. (A) Absolute bacterial
load in each sputum sample calculated by qPCR with universal primers to 16s rRNA gene normalized to gram of sputum extracted for this analysis
(16s molecules (log10)/gram sputum). (B) Absolute abundance of P. aeruginosa in each sputum sample calculated by qPCR with primers to rplU, a
reference gene validated as specific to P. aeruginosa, normalized to gram of sputum extracted for this analysis (rplU molecules (log10)/gram
sputum). B, baseline; E, exacerbation; R, recovery; T, treatment.
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Twelve highly prevalent genera account for most of the
sputum communities in our cohort
We and others have previously reported that the sputum
microbiome includes genera other than Pseudomonas
[11,18-20,23]. To characterize the prevalence and abun-
dance of bacterial genera in spontaneously expectorated
sputum, genomic DNA was isolated from all samples
and the V6-V4 region of the 16S rRNA gene was se-
quenced by 454 pyrosequencing, as previously described
[18]. The complete sputum communities and the relative
abundance for each genus for all patient samples are
listed in Additional file 2: Table S2. In all, over 170 bac-
terial genera were detected in these sputum samples.
Despite this large number of organisms, a relatively small
collection of genera account for 90% of the reads in all
samples. Figure 2A shows the relative abundance of the
top 12 genera (Pseudomonas, Streptococcus, Prevotella,
Achromobacter, Staphylococcus, Haemophilus, Fusobac-
terium, Veillonella, Ralstonia, Rothia, Abiotrophia and
Stenotrophomonas) found in our patient cohort.
Relative bacterial abundance within a patient is
correlated with prevalence across all patients
We found a positive correlation between relative abun-
dance and prevalence of bacteria in the CF sputum. That
is, a genus that was highly abundant in one sample was
also highly prevalent across all samples (Figure 2B). For
example, Pseudomonas (red dot, upper right) was found
Figure 2 Relative abundance of top twelve genera. (A) Stacked bar charts of relative abundance (left y-axis) of the top 12 genera for each
patient across a clinical exacerbation show that 12 genera explain 90% of the complexity for all patient samples. (B) Relative abundance of the
top 12 genera are plotted against the prevalence of each genus in the nine complete (BETR, BER) patient samples and show that bacteria that
are highly abundant in a single patient are also highly prevalent across patients. The colored dots indicate those genera that are both highly
abundant and highly prevalent, and the colors correspond to the legend shown in panel A. Colors in panels A and B correspond to genera as
indicated by the legend beneath panel A. (C) The fraction of P. aeruginosa determined by qPCR (rplU detection/16s rRNA detection) correlates to
the fraction of deep-sequencing reads assigned to the Pseudomonas genus. qPCR samples were analyzed six times and the median fraction values
for each sample are shown. There is one outlier in this dataset (sample 206R, shown in red). When this outlier is removed from the analysis, the
linear regression slope is 1.1 and R2 = 0.90. BER, baseline, exacerbation and recovery; BETR, baseline, exacerbation, treatment and recovery; qPCR,
quantitative PCR.
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in 45 of 46 samples with a mean relative abundance of
0.55 when present. The three genera with the highest
relative abundance and prevalence were Pseudomonas,
Streptococcus and Prevotella, genera previously reported
to be abundant in other patient cohorts [11,18-20,23].
qPCR analysis validates deep-sequencing measurements
of Pseudomonas
We sought to confirm the pyrosequencing results by an
independent method. Because the presence of P. aeruginosa
is associated with worsening lung function [7-9] and
Pseudomonas is found in the majority of our patients,
the relative abundance of P. aeruginosa was measured
by qPCR with primers specific to the P. aeruginosa ref-
erence gene rplU, which were previously validated as
specific for P. aeruginosa [18]. The relative abundance
of P. aeruginosa as measured by qPCR (median of six
technical replicates) was plotted versus the relative abun-
dance of Pseudomonas as determined by deep sequencing
(Figure 2C) for all 17 patients. We observed a strong cor-
relation between pyrosequencing and qPCR data with the
exception of one outlier (Figure 2C, red diamond). Exclud-
ing this outlier from the analysis yields a regression slope
of 1.1 with a correlation coefficient of 0.90, indicating that
our qPCR findings validate our pyrosequencing results.
Microbial communities are resilient throughout clinical
exacerbations and cluster by patient not by clinical stage
Assessing the sputum communities in our cohort, we
did not find any evidence of a shift in microbial struc-
ture at exacerbation (Figure 2A). Instead, we found that
sputum communities in a given patient are more similar
to each other than they are to other patients’ communi-
ties at the same clinical stage. We confirmed this obser-
vation by complete hierarchical clustering and principal
coordinate analysis (PCoA; Figure 3).
The relative abundance of Pseudomonas drives most
of the clustering in our cohort (Figure 3A). Samples
dominated by high levels of Pseudomonas are shown at
the right of the top dendrogram and those by low and
medium levels of Pseudomonas are at the left and center.
Hierarchical clustering analysis revealed no evidence for
clustering by clinical stage (Figure 3A). Colored blocks
indicate clinical stages across the top of the heat map.
When an additional analysis of community similarity
(PCoA, Bray-Curtis) was employed to characterize the
population of all patients in this study, we again observed
no clustering of clinical stages (Figure 3B). Consistent with
the hierarchical clustering analysis, a majority of the
difference in the population is described by the amount
of Pseudomonas in the sample. The patient datasets cir-
cled on the right are all dominated by Pseudomonas
(Figure 3B and Additional file 2: Table S2).
In the majority of patients that have a baseline and re-
covery sample, PCoA revealed that the populations either
changed very little (Patients 101, 201 and 205) or that
the recovery sample circles back to the baseline sample
(Patients 100, 200, 204 and 212). These patterns indicate
that while transient changes may occur during exacerba-
tion (most often at the treatment stage), the populations
return to their pre-exacerbation composition. Patient 204
and 206’s sputum communities are distinct from the
majority of patients as they are dominated by Prevotella
and Streptococcus. For Patient 204, who provided all
four BETR samples, the recovery sample is very similar
to the baseline sample despite the unusual community
of this patient, again emphasizing the theme of stability
in sputum bacterial communities.
An exception to the theme outlined above occurred in
Patient 202. For Patient 202, the recovery sample did not
circle back to its pre-exacerbation state, but interestingly,
it moved closer to the majority of samples in the PCoA
plot. Patient 202’s dominant genus at baseline and exacer-
bation stages was Haemophilus, a genus that has a lower
abundance/prevalence ratio among all other samples
analyzed, which was then replaced post-treatment dur-
ing the recovery phase with Staphylococcus, Streptococcus
and Pseudomonas, genera that have higher abundance/
prevalence ratios (Figure 2B). Thus, patient 202’s unusual
sputum bacterial community was replaced by a commu-
nity more common to this and other reported cohorts
[11,17-19,23,32]. Taken together, hierarchical clustering
and principal coordinate analysis show that while there
are detectable changes to the sputum microbiome for
certain individuals, there is no one genus or pattern of
genera correlated with exacerbations across all patients.
Diversity does not correlate with clinical stage
Reduced bacterial diversity in sputum has been correlated
with decreasing lung function as measured by FEV1
[11,16-20,22]. Nevertheless, it appears that a decrease in
bacterial diversity is a poor predictor of acute exacerba-
tions [11,19]. We calculated the Simpson diversity index
(SDI), a measure of the diversity of a sample, for each
of the six patients that have a complete BETR dataset
(Figure 4A and B) and for all patients (Figure 4C). An
SDI of 0 indicates no diversity; an SDI of 1 indicates
maximum diversity. Diversity fluctuates dramatically within
individual patients (Figure 4A). No obvious pattern emerges
that distinguishes one stage from the next when diver-
sity indices are examined on a patient-by-patient basis
(Figure 4A). Analysis of variance showed no significant
association between diversity and status when data were
fitted with a mixed-effect linear model or when aggre-
gated (Figure 4B, six patients with all four BETR sam-
ples, ANOVA, Tukey post-test P > 0.05; Figure 4C, all
patients, paired t-test P > 0.05). Thus, while reduced
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diversity is correlated with decreasing lung function
over a lifetime, on the short-term timescale of an acute
exacerbation, bacterial diversity is not a reliable pre-
dictor of an exacerbation.
No individual genus is predictive of clinical stage
transition
Hierarchical clustering and principal coordinate analysis,
as multivariate statistics, do not readily identify changes
in individual genera that might be associated with clin-
ical transitions. Thus, we employed a mixed-effects lin-
ear model with clinical stage as a categorical fixed effect
and patient as a random effect to identify significant
differences in the abundance of genera as a function
of clinical stage. For example, the relative abundance of
Pseudomonas at baseline is plotted against its relative
abundance at exacerbation (Figure 5A). Pseudomonas
decreases at the transition from baseline to exacerbation
Figure 3 Microbial communities cluster by patient, not by clinical stage. (A) Hierarchical clustering of top 12 genera found in patient samples.
Each clinical BETR stage is designated by color (baseline, green; exacerbation, red; treatment, orange; recovery, blue) along the top of the diagram;
patient number is given across the bottom. The relative abundance for each genus is colored in shades of red (low relative abundance) to yellow or
bright white (high relative abundance) as shown in the color key (upper left). The x-axis of the color key (row Z-score) indicates the number of standard
deviations from the mean relative abundance for each genus. The count histogram indicates the mean counts for all data in sample set. (B) Principal
coordinate analysis of all patients. Clinical stages are represented by colored dots (baseline, green; exacerbation, red; treatment, orange; recovery, blue)
and black lines connect the trajectories of each patient’s microbiome throughout the study. BETR, baseline, exacerbation, treatment and recovery.
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for many patients (points to the right of the dotted line
with a slope of 1). To determine if this apparent de-
crease in Pseudomonas at exacerbation (and any other
observed change in relative abundance for each genus at
each clinical transition) was significant, a mixed-effects
linear model, with clinical stage as a categorical main
effect, was used to fit these data and calculate the coef-
ficient estimate of the model.
The coefficient estimates of the top 12 genera (includ-
ing Pseudomonas) and any other genus that has a coeffi-
cient estimate significantly different from 1 (P < 0.05)
as they transition between clinical stages are shown in
Figure 5B,C,D (bars). However, because we tested many
genera simultaneously, we cannot consider these results
to be predictive without an additional test of statistical
significance, as P-value = 0.05, by definition, yields a false
positive result 5% of the time under the null hypothesis.
For example, with our dataset of roughly 170 genera, we
would expect about 9 genera to reach a significance of
P = 0.05 under the null hypothesis. A Bonferroni correc-
tion of P values to address the family-wise error rate
would require a given genus to achieve a P value of less
than 0.0003 to reach significance, eliminating all genera
from further consideration.
Discussion
We followed 17 adult CF patients as they transitioned
through the BETR stages of a clinical exacerbation.
Overall, we found that the sputum microbiome is distinct
and resilient within patients throughout time, including
over the course of exacerbation and antibiotic treat-
ment. We found no statistically significant difference in
absolute bacterial abundance (Table 1, Figure 1A), absolute
abundance of Pseudomonas (Figure 1B) or composition
(Figure 3) between clinical stages within each patient. The
majority of patients in our cohort had sputum communities
whose dominant members were unperturbed by clinical
exacerbation, and these communities appeared to change
very little from stage to stage (Figures 2A and 3B). Inter-
estingly, for a patient whose baseline and recovery samples
were strikingly different (202), the microbial composition
changed to a community more common to this cohort
and previously reported cohorts during the course of this
study (Figure 3B) [11,17-19,22,23]. Patient 202 received a
unique antibiotic cocktail of colistin, meropenem and
tobramycin and was the only patient in this cohort to
receive colistin (Additional file 1: Table S1). It is pos-
sible that colistin contributed to the dissimilarity of
Patient 202’s baseline and recovery samples, however,
testing this hypothesis would require additional patient
samples. Diversity in this cohort fails to be a predictor
of clinical exacerbation (Figure 4), which agrees with
three recent studies [11,19,20]. We did not observe
the previously reported significant [11] or modest [19]
decrease in diversity at the treatment stage, possibly
due to our small sample size and short timescale. On
a patient-by-patient level, we see wide variation in diver-
sity (Figure 4A), which is masked when diversity indices
are considered in the aggregate (Figure 4B and C),
highlighting the complex, individualized nature of CF
A B
Figure 4 Diversity does not correlate with clinical stage. (A) Simpson diversity index for the six patients with samples from all four stages
(BETR) are color-coded. A mixed-effect linear model with treatment status as a categorical variable was used to identify significant differences in
diversity as a function of clinical status. Analysis of variance showed no significant association between diversity and status. Aggregated Simpson
diversity index (SDI) of the six patients with all four BETR samples (B) or from all seventeen patients (C). There is no statistically significant differ-
ence between stages for patients with all four BETR samples (ANOVA, Tukey post-test, P values all >0.05). Paired t-test for all patients reveals no
statistical difference between any stage (P > 0.05). B, baseline; BETR, baseline, exacerbation, treatment and recovery; E, exacerbation; R, recovery;
SDI, Simpson diversity index; T, treatment.
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sputum communities. We examined how the relative
abundance of each detectable organism changes be-
tween each clinical stage in each patient and were
unable to identify any one genus that signaled a change in
clinical status (Figure 5). Importantly, the stability of
sputum communities observed throughout exacerbation
and antibiotic treatment (Figures 1 and 2A) suggests
that a single sputum sample is a consistent and reliable
method for sampling the bacteria in CF airways. Se-
quencing a patient’s sputum microbiome may therefore
be a cost effective tool for physicians to create a more
complete picture of all bacteria in a patient’s airways,
which may potentially inform treatment strategies in
the clinic.
We were unable to identify a genus or group of genera
that herald a change in clinical stage when the entire
community was considered (Figure 3) or when each genus
was examined one by one (Figure 5). Assessing diversity
on a patient-by-patient basis (Figure 4A) and bacterial
abundance on a genus-by-genus basis (Figure 5) as we
report here highlights the complexity of identifying a
microbial signature of clinical stage in adult CF patients.
Identifying the microbial factors that influence clinical
transition may require monitoring the long-term dynam-
ics of the airway microbiome of many CF patients over
several cycles of exacerbation, such as reported by Zhao
et al. [11], to tease out the microbial factors that are pre-
dictive or indicative of exacerbations. The individualized
Figure 5 Changes in individual bacterial abundance at each clinical transition. (A) Relative abundance of Pseudomonas at baseline and
exacerbation. Each point represents a different patient labeled with patient ID. The dotted line has a slope of 1. Points to the left of the 1 line
indicate an increase in Pseudomonas at exacerbation compared to baseline; points to the right of the 1 line indicate a decrease in Pseudomonas.
Coefficient estimates of each genus for (B) baseline to exacerbation, (C) exacerbation to treatment and (D) treatment to recovery. The top 12
genera from Figure 2 and genera with coefficient estimate significantly different than 1 (P < 0.05) are shown. Bars indicate mean coefficient
estimate; error bars indicate 95% confidence interval of the mean.
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nature of our cohort’s sputum bacterial communities
suggests that a personalized analysis for each patient
may be necessary for such predictive power. It is pos-
sible that the current resolution of sequencing is not
high enough to identify the microbial contribution to
exacerbation onset. Higher resolution sequencing to the
species or strain level and/or transcriptional profiling of
the bacteria in CF sputum may be required to identify
how the microbiome contributes to exacerbations. Such
analyses may reveal changes in the ratios of virulent and
less virulent strains or species, which may drive acute
and chronic infections, respectively, without changing
the overall load of that genus. For instance, CF patients
are known to harbor multiple strains of P. aeruginosa in
their lungs and over time, virulence factors are selected
against, while antibiotic resistance increases [33]. It is
possible that exacerbations are caused by a shift of rela-
tive abundance from a less virulent strain to a more
virulent one during exacerbations. Additionally, Surette
and colleagues correlated the presence of Streptococcus
milleri group (SMG) with poor patient outcomes [34].
Perhaps the ratio of SMG increases at exacerbation and
decreases at treatment without changing the overall
relative abundance of streptococci in the sputum. There-
fore, in addition to higher resolution population level ana-
lyses, focusing studies on the interspecies interactions
of these relatively few highly abundant and highly
prevalent organisms, particularly the response of these
organisms to antibiotics, has potential to be informative
in the treatment of the polymicrobial infections of the
CF airway.
Conclusions
The results presented here show no microbial signature
specific to any clinical stage by any measure as a group
or for individual patients. Instead, we found that the
sputum microbiome is distinct and resilient within pa-
tients throughout time and the stresses of an exacer-
bation and antibiotic treatment. These data support
previous findings that illustrate the complex microbial
environment that exists in the sputum obtained from
CF airways and support previous work demonstrating
that transition to a pulmonary exacerbation is not due
to the simple increase in bacterial load or bloom of
any one genus or group of genera [11-19,21-23,32].
The individualized nature of our cohort’s sputum bac-
terial communities make it difficult to identify general
trends from a single round of exacerbation. In addition to
analyzing the sputum microbiome from sequential rounds
of exacerbation, higher resolution sequencing to the spe-
cies or strain level and/or transcriptional profiling of the
bacteria in CF sputum may reveal microbial factors that
influence clinical transition. Identifying these clinical
transition factors has potential to inform therapeutic
strategies to better treat the polymicrobial infections of
the CF airway.
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